BioSpace News Archive

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in an oral symposium and three poster presentations during the 2021 American Professional Society of ADHD and Related Disorders (APSARD) Vi

- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, MD, President & CEO, will present a Company overview at NobleCon17, Noble Capital Markets Seventeenth Annual Small and Microcap Investor Conference being held virtually January 19th and 20th.

– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director –

- New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -

Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing XCART;, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets; Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 am ET

Echosens, a high-technology company offering the FibroScan family of products, announces acceptance of its article for publication of the findings of an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) to evaluate from the payer’s perspective the cost effectiveness of deploying VCTE / CAP machines (FibroScan®) for detecting and monitoring fatty liver disease (FLD). Scheduled for publication in 2021 by the American Journal of Managed Care,

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that its Cognigen division has awarded a grant to the Department of Pharmacology and Therapeutics at Makerere University in Kampala, Uganda, the country’s largest and oldest institution of higher learning, to fund upgraded internet capabilities, ensuring access to Cognigen’s KIWITM platform.

Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to leverage Nucleai’s artificial intelligence (AI) -powered biomarker research & discovery platform for one of Debiopharm’s clinical stage oncology assets.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at NobleCon17 - Noble Capital Markets’ Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 11:15 AM ET.